Chronic wounds affect approximately 6.5 million patients in the U.S. (~2% of the population) and represent a significant public health threat due to a rising geriatric population, difficult to treat infections caused by antibiotic-resistant organisms, and comorbidities, including diabetes and obesity. Additionally, research has shown that 60–90% of chronic wounds are associated with biofilms, which can further compromise wound healing and closure, and delay patient recovery.
With the trend towards more evidence-based medicine, several new products and modalities have been or are currently in development to meet the current needs for advanced wound care, such as antimicrobial dressings, bio-engineered tissue products, biomaterials, bioactive dressings, and novel anti-infectives.
iFyber has a wide-ranging offering for developers of advanced, surgical, and traditional wound care products at all stages of development—from the preclinical and screening stages to 510(k) submission and support.
Examples of relevant materials for antimicrobial, fluid and protein transfer, and barrier effectiveness testing include:
- Solid antimicrobial wounds dressings (e.g., foam-based dressings, film-based dressings, woven and non-woven textiles)
- Gels, creams, and ointments
- Topical wound agents
- Wound washes
- Novel antibiotics/biocides
- Coated and uncoated natural tissue matrices
Contact us today to discuss the appropriate testing strategy for your wound care technology.